NASDAQ:ADRO Aduro Biotech (ADRO) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ADRO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.28▼$14.6052-Week Range N/AVolume171,500 shsAverage Volume162,237 shsMarket Capitalization$236.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aduro Biotech alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Aduro Biotech Stock (NASDAQ:ADRO)Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. ADRO Stock News HeadlinesFebruary 24, 2024 | morningstar.comAduro Clean Technologies Inc Ordinary SharesJanuary 3, 2024 | morningstar.comPT Adaro Energy Indonesia TbkApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.December 2, 2023 | morningstar.comPT Adaro Energy Indonesia Tbk ADRONovember 16, 2023 | benzinga.comLegend Biotech Stock (NASDAQ:LEGN), Analyst Ratings, Price Targets, PredictionsNovember 10, 2023 | seekingalpha.comBret JensenNovember 6, 2023 | reuters.comConcord Biotech LtdJune 26, 2023 | thestreet.comAduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage StudyApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 18, 2023 | finance.yahoo.comFrench biotech Sensorion does not expect any impact to its liquidity from SVB's closureMarch 15, 2023 | reuters.comSVB shock could have chilling effect on British biotech sectorMarch 15, 2023 | cnbc.comSVB fallout: The impacts on the biotech sectorDecember 17, 2022 | thestreet.comCancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO DebutNovember 30, 2022 | finance.yahoo.comAduro Selected for Shell GameChanger ProgramOctober 29, 2022 | barrons.comMerck’s CFO Says Biotech Deals are Getting DoneSeptember 28, 2022 | finance.yahoo.comPT Adaro Energy Indonesia Tbk (ADRO.JK)July 31, 2021 | barrons.comAdaro EnergySee More Headlines Receive ADRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/04/2020Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADRO CUSIPN/A CIK1435049 Webwww.aduro.com Phone(206) 485-7051FaxN/AEmployees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,370,000.00 Net Margins-230.92% Pretax MarginN/A Return on Equity-101.73% Return on Assets-22.35% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual Sales$17.26 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / BookN/AMiscellaneous Outstanding Shares16,212,000Free FloatN/AMarket Cap$236.61 million OptionableOptionable Beta0.40 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesEric L. DobmeierChairman, President & Chief Executive OfficerAlan GlicklichChief Medical OfficerKirk D. SchumacherSenior Vice President & General CounselTom FrohlichChief Business OfficerNoopur LiffickVP-Investor Relations & Corporate CommunicationsKey CompetitorsWerewolf TherapeuticsNASDAQ:HOWLVanda PharmaceuticalsNASDAQ:VNDAAC ImmuneNASDAQ:ACIUAldeyra TherapeuticsNASDAQ:ALDXPuma BiotechnologyNASDAQ:PBYIView All Competitors ADRO Stock Analysis - Frequently Asked Questions How were Aduro Biotech's earnings last quarter? Aduro Biotech, Inc. (NASDAQ:ADRO) posted its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to the consensus estimate of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%. What other stocks do shareholders of Aduro Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Amarin (AMRN), Anavex Life Sciences (AVXL), Micron Technology (MU), VBI Vaccines (VBIV) and PTC Therapeutics (PTCT). When did Aduro Biotech IPO? Aduro Biotech (ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. This page (NASDAQ:ADRO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aduro Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
